Related Experiment Video
Updated: Jul 5, 2026
13:27
Generation of Human CD40-activated B cells
Published on: October 16, 2009
15.3K
A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma
Pierre V Candelaria1, Miguel Nava1, Tracy R Daniels-Wells1
1Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Cancers
|September 28, 2023
Summary
A novel anti-CD38 IgE antibody shows promise for treating multiple myeloma (MM). This engineered antibody effectively targets cancer cells and activates immune responses, prolonging survival in preclinical models.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Multiple myeloma (MM) is an incurable plasma cell malignancy.
- IgE antibodies offer unique therapeutic advantages over IgG for cancer treatment.
- Fc receptors (FcεRs) on immune cells mediate anti-cancer effector functions.
Purpose of the Study:
- To develop and evaluate a fully human IgE antibody targeting CD38 for MM therapy.
- To assess the binding, effector functions, and in vivo efficacy of the anti-CD38 IgE.
Main Methods:
- Development of a novel anti-CD38 IgE antibody.
- In vitro characterization of antibody binding and FcεR interaction.
- Assessment of antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP).
- In vivo efficacy studies in xenograft mouse models.
Main Results:
- The anti-CD38 IgE was properly expressed, assembled, and secreted.
- The antibody demonstrated high-affinity binding to CD38 and FcεRI.
- In vitro and in vivo studies showed induction of effector functions and degranulation.
- The anti-CD38 IgE prolonged survival in a preclinical MM mouse model.
Conclusions:
- The novel anti-CD38 IgE antibody is a promising therapeutic candidate for multiple myeloma.
- This IgE antibody effectively engages immune effector cells against CD38-expressing malignancies.
- Further investigation in human clinical trials is warranted.
